• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

FDA staff raise no major concerns about Eli Lilly Alzheimer's drug

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 06, 2024 at 09:22: PM
via An FDA analysis of trial data for Eli Lilly's (LLY.N), experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.

article source
 

<



Similar threads

cafead
US FDA staff questions confirmatory trial data for Intercept&#039;s liver disease drug
Replies
0
Views
32
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA staff flags risk of low blood sugar for Novo Nordisk&#039;s weekly insulin
Replies
0
Views
67
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA staff says Guardant&#039;s test may fail to detect some pre-cancerous tumors
Replies
0
Views
69
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA staff raises concerns over data from J&amp;J, Bristol&#039;s CAR-T therapies
Replies
0
Views
96
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA staff raises concerns on Geron&#039;s blood disorder drug
Replies
0
Views
91
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote